** Shares of Senti Biosciences SNTI.O more than double to $5.23; last up 139.5%
** Co says its cell therapy for cancer that has either come back or stop responding to treatment caused a complete remission in 2 of 3 patients in an early-stage trial
** Complete remission is the disappearance of all signs of cancer in response to treatment
** SNTI says additional safety and efficacy data, including initial durability data on the therapy SENTI-202, are expected to follow in 2025
** Co says it has also entered into a securities purchase agreement with some investors to issue and sell about 16,713 Series A preferred stock through a private investment in public equity or PIPE financing
** SNTI expects gross proceeds from financing to be about $37.6 mln, plans to use them along with existing cash towards SENTI-202 development and manufacturing, other R&D activities, and for general corporate purposes
** Up to last close, stock down 67.3% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。